Condition:  Autoimmune Hepatitis

Help Advance Autoimmune Hepatitis (AIH) Research

Explore the MERCURY Study: Now enrolling adults with autoimmune hepatitis (AIH).

You may be eligible to join a clinical study exploring if a study drug may help control liver inflammation and reduce the long-term need for steroids in AIH.

Who Can Join
• Adults between the ages of 18–75
• Diagnosed with autoimmune hepatitis
• Symptoms that have not responded well or intolerant to current treatment options for AIH

Why Consider Participating
• Access to physicians with experience working with AIH
• Reasonable reimbursement for travel-related expenses
• The opportunity for eligible participants to receive the study drug during the optional open-label period

Learn More or See If You Qualify

A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/mirikizumab co-administration compared with mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

Condition:  Crohn’s Disease

Testing for: Mirikizumab (LY3074828) and LY4395089

Trial ID: J6Z-MC-CD01

Age: 18 to 80

Phase: 2

A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line Treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer (SUNRAY-02)

Condition:  Non-Small Cell Lung Cancer

Testing For: Olomorasib (LY3537982)

Trial ID: J3M-MC-JZQB

Age: Age: 18+

Study Title A Phase 3, randomized, modified double-blind, active controlled, parallel-group, 2-arm study to investigate the safety and immunogenicity of a single dose of a 21-valent pneumococcal conjugate vaccine in children and adolescents with sickle cell disease

Condition:  Sickle Cell Disease

Summary: this study is testing a new vaccine that protects against 21 types of pneumococcal bacteria. The study involves children and teenagers with sickle cell disease. Two-thirds of the participants will receive the new vaccine, and one-third will receive an existing, standard pneumococcal vaccine (the 'active control'). Participants are randomly assigned to groups. Researchers will compare how safe the new vaccine is and how well it helps the body's immune system fight disease. Each person gets 1 dose of the vaccine, and the study is designed so that neither the participants nor most of the researchers know who got which vaccine until the study is complete this helps ensure fair, unbiased results.

Age: 2-17

Phase: 3

A clinical trial for people who have irritable bowel syndrome with diarrhea (GZMS) (RENEW-IBS-D)

Condition:  Irritable Bowel Syndrome-Diarrhea (IBS-D)

What the trial is testing: Brenipatide

Trial ID: J3S-MC-GZMS

Age: 18 to 75 years of age

Phase: 2

A Clinical trial for people with irritable bowel syndrome with constipation (GZMT) (RENEW-IBS-C)

Condition:  Irritable Bowel Syndrome-Constipation (IBS-C)

What the trial is testing: Brenipatide

Trial ID: J3S-MC-GZMT

Age: 18 to 75 years of age

Phase: 2

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET).

Condition:  Crohn's Disease

A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease

Drugs: LY4268989 (MORF-057)

Trial ID: J6E-MC-KWAB

Age: 18 to 85

Phase: 2

Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Condition:  Non-Segmental Vitiligo

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAD

Age: 18 to ≤75 years of age

Phase: 2

Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Severe Alopecia Areata

Condition:  Severe Alopecia Areata

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAC

Age: 18 to ≤50 years of age

Phase: 2

EMERALD-3: A Phase 2b/3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis

Condition:  Ulcerative Colitis

Testing for: LY4268989 (MORF-057)

Trial ID: J6E-MC-KWAM

Age: 18 - 80

Phase: 2 and 3

We’re helping to connect individuals with a clinical study for adults living with uncontrolled gout. Uncontrolled gout occurs when gout symptoms keep coming back despite taking medication, causing repeated flare-ups, lingering joint pain, and sometimes hard lumps under the skin called tophi.

Condition:  Gout

The Kadence study is being conducted to evaluate the safety and efficacy of the study drug administered as a subcutaneous injection compared to an IV infusion in adults with uncontrolled gout. If approved, the subcutaneous administration of the study drug may offer a more convenient approach to managing uncontrolled gout.

This study is looking for about 270 adults who have been diagnosed with uncontrolled gout to participate.

What to Expect

• Regular visits and follow ups with a study team 

• Study drug administration

• Safety monitoring 

• Support from a study team 

Why Consider Participating

• Every participant receives the study drug at no charge using one of two delivery methods

• Access to physicians with experience working with gout

• Reasonable reimbursements for travel-related expenses may be available

• Potentially help move research forward for other people with goutcipate.

A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)

Condition:  Ovarian Cancer

Testing for: LY4170156, mirvetuximab soravtansine, topotecan, bevacizumab, paclitaxel, carboplatin, gemcitabine

Trial ID: J5E-MC-JZXB

Age: ≥18 years

Phase: 3